Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Consensus Recommendation of “Buy” by Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been given an average recommendation of “Buy” by the five research firms that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have covered the stock in the last year is $36.60.

KNSA has been the subject of several research analyst reports. Evercore ISI upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. upped their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Finally, Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price on the stock.

Insider Activity

In other news, COO Eben Tessari sold 17,000 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the completion of the sale, the chief operating officer now owns 109,975 shares in the company, valued at approximately $2,955,028.25. This trade represents a 13.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares in the company, valued at $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,092 shares of company stock valued at $673,039. Company insiders own 54.57% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Several large investors have recently bought and sold shares of KNSA. Quarry LP acquired a new stake in shares of Kiniksa Pharmaceuticals during the third quarter valued at about $50,000. CWM LLC grew its stake in Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares in the last quarter. nVerses Capital LLC purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $80,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the 2nd quarter valued at approximately $100,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $189,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ:KNSA opened at $20.01 on Friday. The company has a market cap of $1.44 billion, a P/E ratio of -142.92 and a beta of 0.27. The business has a fifty day simple moving average of $22.13 and a 200-day simple moving average of $23.12. Kiniksa Pharmaceuticals has a 52 week low of $16.56 and a 52 week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The business had revenue of $112.21 million during the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm’s quarterly revenue was up 67.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.20) EPS. Sell-side analysts expect that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.